Prevention by calcium antagonists of profibrillatory effects of class I antiarrhythmic drugs in acute myocardial ischemia: Study in pig heart in situ

Pharmacotherapy

Volumn 17, Issue 4, 1997, Pages 737-745

  Bui Xuan, Bernard ^a   Aupetit, Jean F ^b   Freysz, Marc ^a   Faucon, Georges ^a   Timour, Quadiri ^a  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE HOSPITALIER SAINT JOSEPH SAINT LUC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM ANTAGONIST; DILTIAZEM; FLECAINIDE;

ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; DRUG EFFECT; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; NONHUMAN; SWINE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; FEMALE; FLECAINIDE; HEART CONDUCTION SYSTEM; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; SWINE; VENTRICULAR FIBRILLATION;

EID: 0030762607     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-47.
2. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
3. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Mortality and morbidity in patients receiving encainide. N Engl J Med 1991;324:781-8.
4. Hine LK, Laird N, Hewitt P, Chalmers TC. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 1989;149:2694-8.
5. Antman EM, Berlin JA. Declining incidence of ventricular fibrillation in myocardial infarction: implications for the prophylactic use of lidocaine. Circulation 1992;86:764-73.
6. Timour Q, Aupetit JF, Loufoua-Moundanga J, Gerentes-Chassagne I, Kioueh I, Faucon G. Class I antiarrhythmic drugs and myocardial ischaemia: study in the pig heart in situ. Naunyn Schmiedeberg's Arch Pharmacol 1991;343:645-51.
7. Aupetit JF, Timour Q, Larbre JP, et al. Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia. Cardiovasc Drugs Ther 1993;7:217-23.
8. Aupetit JF, Timour Q, Loufoua-Moundanga J, et al. Profibrillatory effects of lidocaine in the acutely ischemic porcine heart. J Cardiovasc Pharmacol 1995;25:810-16.
9. Timour Q, Aupetit JF, Chevrel G, Loufoua-Moundanga J, Omar S., Faucon G. Time course of electrical fibrillation threshold in brief periods of myocardial ischemia and genesis of fibrillation: role of calcium. Cardiovasc Drugs Ther 1994;8:877-9.
10. Timour Q, Aupetit JF, Loufoua-Moundanga J, et al. Role of asynchronous activation of the ventricular fibres by an ectopic pacemaker in the accidents, especially fibrillation, caused by Ic antiarrhythmic drugs. Fundam Clin Pharmacol 1992;62:152-67.
11. Coraboeuf E. Ionic basis of electrical activity in cardiac tissues. Am J Physiol 1978;234:H101-16.
12. Reuter H. Ion channels in cardiac cell membrane. Annu Rev Physiol 1984;46:473-84.
13. Campbell TU, Vaughan Williams EM. Voltage- and time-dependent depression of maximum rate of depolarization of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc Res 1983;17:251-8.
14. Kaumann AJ, Aramendia P. Prevention of ventricular fibrillation induced by coronary ligation. J Pharmacol Exp Ther 1968;164:326-32.
15. Brooks WW, Verrier RL, Lown B. Protective effect of verapamil on vulnerability to ventricular fibrillation during myocardial ischemia and reperfusion. Cardiovasc Res 1980;14:295-302.
16. Clusin WT, Buchbinder M, Ellis AK, Kernoff RS, Giacomini JC, Harrison DC. Reduction of ischemic depolarization by the calcium channel blocker diltiazem. Circ Res 1984;54:10-20.
17. Aupetit JF, Timour Q, Chevrel G, Loufoua-Moundanga J, Omar S, Faucon G. Attenuation of the ischaemia-induced fall of electrical threshold for fibrillation by a calcium antagonist, diltiazem. Naunyn Schmiedeberg's Arch Pharmacol 1993;348:509-14.
18. Multicenter Diltiazem Postinfarction Trial (MDPIT) Investigators. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
19. Danish Verapamil Infarction Trial II (DAVIT II) Investigators. Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 1990;66:779-85.
20. Hagar JM, Hale SL, Kloner RA. Effect of preconditioning ischemia on reperfusion in the rat. Circ Res 1991;68:61-8.
21. Vegh A, Komori S, Szekeres L, Parratt JR. Antiarrhythmic effects of preconditioning in anesthetised dogs and rats. Cardiovasc Res 1992;26:487-95.
22. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay in lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36.
23. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049-1169.
24. Aupetit JF, Freysz M, Faucon G, Loufoua J, Timour Q. Change of a beneficial effect into an untoward effect by ischemia: effect of quinidine-like drugs on vulnerability to ventricular fibrillation. Environ Toxicol Pharmacol 1996;2:1-7.
25. Aupetit JF, Loufoua-Moundanga J, Faucon G, Timour Q. Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation. Br J Pharmacol 1997;120:535-9.
26. Timour Q, Larbre JP, Aupetit JF, et al. Protection against ischaemic ventricular fibrillation by blocking agents of myocardial cell calcium influx. Electrophysiological study in the pig in situ heart. Fundam Clin Pharmacol 1991;5:641-4.
27. Timour Q, Larbre JP, Kioueh I, et al. Calcium channel modulators and susceptibility to ischaemic ventricular fibrillation: modification of cellular calcium overload. Arch Int Pharmacodyn 1992;315:30-46.
28. Aupetit JF, Timour Q, Freysz M, et al. Vulnerability to ventricular fibrillation related to ischaemia. Comparison of the acute effects of β-blockers and calcium antagonists. Arch Int Pharmacodyn 1994;327:25-39.
29. Timour Q, Bui-Xuan B, Faucon G, Aupetit JF. Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia. Cardiovasc Drugs Ther 1996;10:447-54.
30. Weidmann S. The effect of the cardiac membrane potential on the rapid availability of sodium carrying system. J Physiol (Lond) 1955;127:213-14.
31. Lyons CJ, Burgess MJ, Abildskov JA. Effects of acute hyperkalemia on cardiac excitability. Am Heart J 1977;94:755-63.
32. Merx W, Yoon MS, Han J. The role of local disparity in conduction and recovery time on ventricular vulnerability to fibrillation. Am Heart J 1977;94:603-10.
33. Puddu PE, Bourassa MG. Prediction of sudden death from QTc interval prolongation in patients with chronic ischemic heart disease. J Electrocardiol 1986;19:203-11.
34. Day CP, McComb JM, Campbell RW. QT dispersion and indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990;63:342-4.
35. Clusin WT, Bristow MR, Karagueuzian HS, Katzung BG, Schroeder JS. Do calcium-dependent ionic currents mediate ischemic ventricular fibrillation? Am J Cardiol 1982;49:606-12.
36. + accumulation. Eur J Pharmacol 1986;127:261-5.
37. Gettes LS, Cascio WE, Johnson T, Fleet WF. Local myocardial biochemical and ionic alterations during myocardial ischemia and reperfusion. Drugs 1991;42(suppl 1):7-13.
38. Heijnis JB, Coronel R, Van Zwieten PA. The effects of calcium antagonists on extracellular potassium accumulation during global ischemia in isolated perfused rat hearts. Cardiovasc Drugs Ther 1991;5:1035-41.
39. Lang J, Timour Chah Q, Charve P, Aupetit JF, El Chebly M, Faucon G. Role of calcium in the rate-dependent depression of atrioventricular nodal conduction in the dog heart under vagal influence. Int J Cardiol 1987;15:65-76.
40. Timour Chah Q, Bertrix L, Bouzouita K, Lang J, Faucon G. Study of the ventricular antifibrillatory effects of calcium channel blocking agents in comparison with lidocaine on canine normal heart in situ. Arch Int Pharmadoyn 1983;261:238-48.